A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

CLL
Chronic Lymphocytic Leukemia

Interventions

DRUG: BGB-16673
DRUG: Bendamustine
DRUG: Idelalisib
DRUG: Rituximab
DRUG: Venetoclax

Sponsor

BeOne Medicines